GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » OncoCyte Corp (LTS:0KCC) » Definitions » Price-to-Owner-Earnings

OncoCyte (LTS:0KCC) Price-to-Owner-Earnings : (As of Apr. 28, 2024)


View and export this data going back to 2018. Start your Free Trial

What is OncoCyte Price-to-Owner-Earnings?

As of today (2024-04-28), OncoCyte's share price is $82.60. OncoCyte does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for OncoCyte's Price-to-Owner-Earnings or its related term are showing as below:


LTS:0KCC's Price-to-Owner-Earnings is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 25.395
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-04-28), OncoCyte's share price is $82.60. OncoCyte's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.55. Therefore, OncoCyte's PE Ratio for today is At Loss.

As of today (2024-04-28), OncoCyte's share price is $82.60. OncoCyte's EPS without NRI for the trailing twelve months (TTM) ended in was $-3.43. Therefore, OncoCyte's PE Ratio without NRI for today is At Loss.

During the past 11 years, OncoCyte's highest PE Ratio without NRI was 9.33. The lowest was 0.00. And the median was 6.62.


OncoCyte Price-to-Owner-Earnings Historical Data

The historical data trend for OncoCyte's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoCyte Price-to-Owner-Earnings Chart

OncoCyte Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

OncoCyte Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of OncoCyte's Price-to-Owner-Earnings

For the Diagnostics & Research subindustry, OncoCyte's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoCyte's Price-to-Owner-Earnings Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, OncoCyte's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where OncoCyte's Price-to-Owner-Earnings falls into.



OncoCyte Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

OncoCyte's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=82.60/-130.56
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OncoCyte  (LTS:0KCC) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


OncoCyte Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of OncoCyte's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoCyte (LTS:0KCC) Business Description

Traded in Other Exchanges
Address
15 Cushing, Irvine, CA, USA, 92618
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States.

OncoCyte (LTS:0KCC) Headlines

No Headlines